

# Mingjun Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5194969/publications.pdf>

Version: 2024-02-01

29  
papers

1,127  
citations

516710

16  
h-index

501196

28  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2409  
citing authors

#	ARTICLE	IF	CITATIONS
1	TAK1 Negatively Regulates NF- $\kappa$ B and p38 MAP Kinase Activation in Gr-1+CD11b+ Neutrophils. <i>Immunity</i> , 2012, 36, 43-54.	14.3	149
2	Critical role of histone demethylase Jmjd3 in the regulation of CD4+ T-cell differentiation. <i>Nature Communications</i> , 2014, 5, 5780.	12.8	136
3	Current advances in T-cell-based cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 1265-1278.	2.0	119
4	Cross-Regulation of Two Type I Interferon Signaling Pathways in Plasmacytoid Dendritic Cells Controls Anti-malaria Immunity and Host Mortality. <i>Immunity</i> , 2016, 45, 1093-1107.	14.3	100
5	CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. <i>Vaccine</i> , 2007, 25, 2823-2831.	3.8	94
6	Strain-specific innate immune signaling pathways determine malaria parasitemia dynamics and host mortality. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E511-20.	7.1	74
7	Microbiota regulate innate immune signaling and protective immunity against cancer. <i>Cell Host and Microbe</i> , 2021, 29, 959-974.e7.	11.0	67
8	The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. <i>Cancer Letters</i> , 2006, 231, 247-256.	7.2	50
9	Inflammasome activation negatively regulates MyD88-IRF7 type I IFN signaling and anti-malaria immunity. <i>Nature Communications</i> , 2018, 9, 4964.	12.8	46
10	LRRC25 Functions as an Inhibitor of NF- $\kappa$ B Signaling Pathway by Promoting p65/RelA for Autophagic Degradation. <i>Scientific Reports</i> , 2017, 7, 13448.	3.3	43
11	Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered T cells in a phase I clinical trial: A case report. <i>Oncology Letters</i> , 2018, 16, 6998-7007.	1.8	29
12	Identification of MHC class II restricted T-cell-mediated reactivity against MHC class I binding Mycobacterium tuberculosis peptides. <i>Immunology</i> , 2011, 132, 482-491.	4.4	28
13	Classification of Human Leukocyte Antigen (HLA) Supertypes. <i>Methods in Molecular Biology</i> , 2014, 1184, 309-317.	0.9	26
14	HLA Class I Binding 9mer Peptides from Influenza A Virus Induce CD4+ T Cell Responses. <i>PLoS ONE</i> , 2010, 5, e10533.	2.5	24
15	Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1755-1763.	4.2	22
16	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2014, 32, 235-242.	2.6	21
17	Orthotopic porcine corneal xenotransplantation using a human graft. <i>Acta Ophthalmologica</i> , 2009, 87, 917-919.	1.1	14
18	Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy. <i>PLoS ONE</i> , 2012, 7, e45756.	2.5	13

#	ARTICLE	IF	CITATIONS
19	Identification of MHC Class I H-2 Kb/Db-Restricted Immunogenic Peptides Derived from Retinal Proteins. , 2006, 47, 3939.		12
20	Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers. Immunology Letters, 2019, 216, 51-62.	2.5	12
21	Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. PLoS ONE, 2015, 10, e0124094.	2.5	9
22	Identification of Special AT-Rich Sequence Binding Protein 1 as a Novel Tumor Antigen Recognized by CD8+ T Cells: Implication for Cancer Immunotherapy. PLoS ONE, 2013, 8, e56730.	2.5	8
23	Murrangatin suppresses angiogenesis induced by tumor cell&ndash;derived media and inhibits AKT activation in zebrafish and endothelial cells. Drug Design, Development and Therapy, 2018, Volume 12, 3107-3115.	4.3	8
24	Phenotypic analysis of tumor-infiltrating lymphocytes from non-small cell lung cancer and their potential application for adoptive cell therapy. Immunopharmacology and Immunotoxicology, 2020, 42, 319-329.	2.4	7
25	Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines Against Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 224, 956-966.	4.0	6
26	Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors. Cancer Letters, 2007, 251, 86-95.	7.2	4
27	Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine&2,3&di;oxygenase in microenvironment of nonsmall cell lung cancer. Hla, 2019, 94, 39-48.	0.6	2
28	Next Generation Sequencing&B;Based Identification of T&C;Cell Receptors for Immunotherapy Against Hepatocellular Carcinoma. Hepatology Communications, 2021, 5, 1106-1119.	4.3	2
29	Phase I trial of NY-ESO-1/LAGE1 peptide vaccine for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2012, 30, 4643-4643.	1.6	2